Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial

por Stinchcombe, Thomas E.
Publicado 2023

Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab

por Stinchcombe, Thomas E
Publicado 2007

Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy

por Stinchcombe, Thomas E.
Publicado 2014

Recent advances in the treatment of non-small cell and small cell lung cancer

por Stinchcombe, Thomas E.
Publicado 2014

Current management of RET rearranged non-small cell lung cancer

por Stinchcombe, Thomas E
Publicado 2020

Narrative review: blood and tumor biomarker testing in non-small cell lung cancer without an oncogenic driver

por Stinchcombe, Thomas E.
Publicado 2023

Characteristics of toxicity occurrence patterns in concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced non-small cell lung cancer: a pooled...

por Yang, Lexie Zidanyue, He, Qihua, Zhang, Jianrong, Ganti, Apar Kishor, Stinchcombe, Thomas E., Pang, Herbert, Wang, Xiaofei
Publicado 2022

Using a Clinically Interpretable End Point Composed of Multiple Outcomes to Evaluate Totality of Treatment Effect in Comparative Oncology Studies

por Wang, Xiaofei, McCaw, Zachary R., Tian, Lu, Stinchcombe, Thomas E., Vokes, Everett, Ludmir, Ethan B., Wei, Lee-Jen
Publicado 2023

Adopting Consensus Terms for Testing in Precision Medicine

por Martin, Nikki A., Tepper, Joel E., Giri, Veda N., Stinchcombe, Thomas E., Cheng, Heather H., Javle, Milind M., Konnick, Eric Q.
Publicado 2021

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort

por Fairclough, Stephen R., Kiedrowski, Lesli A., Lin, Jessica J., Zelichov, Ori, Tarcic, Gabi, Stinchcombe, Thomas E., Odegaard, Justin I., Lanman, Richard B., Shaw, Alice T., Nagy, Rebecca J.
Publicado 2019

Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic

por Kumar, Sameera, Chmura, Steven, Robinson, Clifford, Lin, Steven H., Gadgeel, Shirish M., Donington, Jessica, Feliciano, Josephine, Stinchcombe, Thomas E., Werner-Wasik, Maria, Edelman, Martin J., Moghanaki, Drew
Publicado 2020

A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial

por Clarke, Jeffrey M., Gu, Lin, Wang, Xiaofei F., Stinchcombe, Thomas E., Stevenson, Marvaretta M., Ramalingam, Sundhar, Shariff, Afreen, Garst, Jennifer, Nixon, Andrew B., Antonia, Scott J., Crawford, Jeffrey, Ready, Neal E.
Publicado 2022

JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer

por Ramalingam, Suresh S., Thara, Eddie, Awad, Mark M., Dowlati, Afshin, Haque, Basir, Stinchcombe, Thomas E., Dy, Grace K., Spigel, David R., Lu, Sharon, Iyer Singh, Nithya, Tang, Yongqiang, Teslenko, Iryna, Iannotti, Nicholas
Publicado 2021

Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastati...

por Hensing, Thomas A., Wang, Xiaofei, Stinchcombe, Thomas E., Gao, Junheng, Knopp, Michael V., Watson, Mark, Dudek, Arkadiusz Z., Graziano, Stephen L., Patel, Jyoti D., Faller, Bryan A., Dragnev, Konstantin H., Kozono, David, Vokes, Everett E.
Publicado 2021

Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Tre...

por Wang, Xiaofei, Wang, Xiaoyi, Hodgson, Lydia, George, Stephen L., Sargent, Daniel J., Foster, Nate R., Ganti, Apar Kishor, Stinchcombe, Thomas E., Crawford, Jeffrey, Kratzke, Robert, Adjei, Alex A., Kindler, Hedy L., Vokes, Everett E., Pang, Herbert
Publicado 2017

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

por Apolo, Andrea B., Infante, Jeffrey R., Balmanoukian, Ani, Patel, Manish R., Wang, Ding, Kelly, Karen, Mega, Anthony E., Britten, Carolyn D., Ravaud, Alain, Mita, Alain C., Safran, Howard, Stinchcombe, Thomas E., Srdanov, Marko, Gelb, Arnold B., Schlichting, Michael, Chin, Kevin, Gulley, James L.
Publicado 2017

Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)

por Sands, Jacob M, Mandrekar, Sumithra J, Kozono, David, Oxnard, Geoffrey R, Hillman, Shauna L, Wigle, Dennis A, Govindan, Ramaswamy, Carlisle, Jennifer, Gray, Jhanelle, Salama, Joseph K, Raez, Luis, Ganti, Apar, Foster, Nathan, Malik, Shakun, Bradley, Jeffrey, Kelly, Karen, Ramalingam, Suresh S, Stinchcombe, Thomas E
Publicado 2021

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial

por Gettinger, Scott N., Redman, Mary W., Bazhenova, Lyudmila, Hirsch, Fred R., Mack, Philip C., Schwartz, Lawrence H., Bradley, Jeffrey D., Stinchcombe, Thomas E., Leighl, Natasha B., Ramalingam, Suresh S., Tavernier, Susan S., Yu, Hui, Unger, Joseph M., Minichiello, Katherine, Highleyman, Louise, Papadimitrakopoulou, Vassiliki A., Kelly, Karen, Gandara, David R., Herbst, Roy S.
Publicado 2021

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400...

por Leighl, Natasha B, Redman, Mary W, Rizvi, Naiyer, Hirsch, Fred R, Mack, Philip C, Schwartz, Lawrence H, Wade, James L, Irvin, William J, Reddy, Sreekanth C, Crawford, Jeffrey, Bradley, Jeffrey D, Stinchcombe, Thomas E, Ramalingam, Suresh S, Miao, Jieling, Minichiello, Katherine, Herbst, Roy S, Papadimitrakopoulou, Vassiliki A, Kelly, Karen, Gandara, David R
Publicado 2021